Last reviewed 2026-04-23 · How we verify

NanoFlu

NanoFlu is a recombinant nanoparticle-based influenza vaccine that displays hemagglutinin proteins on virus-like particles to stimulate robust immune responses.

NanoFlu is a recombinant nanoparticle-based influenza vaccine that displays hemagglutinin proteins on virus-like particles to stimulate robust immune responses. Used for Prevention of seasonal influenza in adults.

At a glance

Mechanism of action

NanoFlu uses self-assembling nanoparticles derived from recombinant hemagglutinin (HA) protein to create a highly immunogenic vaccine platform. The nanoparticle structure presents multiple copies of HA antigen in a particulate form, which enhances recognition by the immune system and promotes stronger antibody and T-cell responses compared to traditional inactivated influenza vaccines. This approach aims to provide improved efficacy and broader protection against seasonal influenza.

Approved indications

• Prevention of seasonal influenza in adults

Common side effects

• Injection site pain or erythema
• Myalgia
• Fatigue
• Headache

Key clinical trials

• Phase 3 Pivotal Trial of NanoFlu™ in Older Adults (PHASE3)
• Evaluation of the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix M-1 Adjuvant (NanoFlu) (PHASE1, PHASE2)
• Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• NanoFlu CI brief — competitive landscape report
• NanoFlu updates RSS · CI watch RSS
• Novavax portfolio CI